Source - LSE Regulatory
RNS Number : 9818G
ConvaTec Group PLC
30 November 2020
 

30 November 2020

ConvaTec Group Plc
("ConvaTec" or "the Company")
Director/PDMR Shareholding

 

The Company has been notified of the following transaction by a Person Discharging Managerial Responsibility ("PDMR") in ordinary shares of 10 pence each in the share capital of the Company ("Shares").

The Company has been informed that Shares held by Mr Karim Bitar, Chief Executive Officer and a PDMR, were transferred into nominee accounts for nil consideration. The transfer of Shares into each nominee account completed as follows:  

1.         616,234 Shares on 25 November 2020

2.         989,830 Shares on 26 November 2020

No change to the number of Shares beneficially held by Mr Bitar has occurred in connection with the transfer of Shares and Mr Bitar remains interested in the 1,606,064 Shares.

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Karim Bitar

2

Reason for the notification

a)

Position/Status

Chief Executive Officer

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

ConvaTec Group Plc

b)

LEI

213800LS272L4FIDOH92

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 10p each in ConvaTec Group Plc ("Shares")

GB00BD3VFW73

b)

Nature of the transaction

Transfer of 616,234 Shares to a nominee account.

c)

Price(s) and volume(s)

Price(s)

N/A

 

Volume(s)

616,234

d)

Aggregated information

- Aggregated volume 

- Price

 

N/A

N/A

e)

Date of the transaction

25 November 2020

f)

Place of the transaction

Outside of a trading venue

 

 

 

 

 

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Karim Bitar

2

Reason for the notification

a)

Position/Status

Chief Executive Officer

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

ConvaTec Group Plc

b)

LEI

213800LS272L4FIDOH92

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 10p each in ConvaTec Group Plc ("Shares")

GB00BD3VFW73

b)

Nature of the transaction

Transfer of 989,830 Shares to a nominee account

c)

Price(s) and volume(s)

Price(s)

N/A

 

Volume(s)

989,830

d)

Aggregated information

- Aggregated volume 

- Price

 

N/A

N/A

e)

Date of the transaction

26 November 2020

f)

Place of the transaction

Outside of a trading venue

 

 

 

 

 

 

 

 

 

 

 

Enquiries

Analysts and Investors

Kate Postans, VP Investor Relations &

Corporate Communications, ConvaTec,                                              +44 (0)7826 447807

ir@convatec.com

 

Media

Buchanan: Charles Ryland / Chris Lane                                              +44 (0)207 466 5000                                                                                                        

ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92

About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. Our vision, which encompasses our purpose, is: Pioneering trusted medical solutions to improve the lives we touch. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFLFFELTLIVII
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.